Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 91.11
- Piotroski Score 4.00
- Grade Outperform
- Symbol (EWTX)
- Company Edgewise Therapeutics, Inc.
- Price $35.91
- Changes Percentage (4.13%)
- Change $1.43
- Day Low $33.64
- Day High $36.09
- Year High $36.66
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/06/2024
- Fiscal Year End N/A
- Average Stock Price Target $42.00
- High Stock Price Target $51.00
- Low Stock Price Target $42.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.54
- Trailing P/E Ratio -11.47
- Forward P/E Ratio -11.47
- P/E Growth -11.47
- Net Income $-100,163,000
Income Statement
Quarterly
Annual
Latest News of EWTX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Edgewise Therapeutics, Inc. (EWTX): A Hot Stock to Buy Now
A list of hot stocks includes Edgewise Therapeutics, Inc. (NASDAQ:EWTX) due to its promising developments in treating muscle diseases. Analysts are bullish on EWTX, expecting significant value increas...
By Yahoo! Finance | 4 weeks ago
